(Q37062906)

18 August 2017

1 reference

title

Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders (English)

1 reference

18 August 2017

0 references

D J McCann

1

1 reference

PubMed ID

18212797

18 August 2017

language of work or name

English

0 references

publication date

23 January 2008

1 reference

Clinical Pharmacology & Therapeutics

18 August 2017

1 reference

18 August 2017

83

1 reference

18 August 2017

4

1 reference

18 August 2017

627-630

1 reference

Contrast of Treatment-Seeking and Untreated Cocaine Abusers

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

Naltrexone-buprenorphine interactions: effects on cocaine self-administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

Medication development for addictive disorders: the state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

A double-blind, placebo-controlled trial of modafinil for cocaine dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

A Systematic Review of Modafinil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Buprenorphine suppresses cocaine self-administration by rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Treatment of cocaine abuse with buprenorphine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Buprenorphine treatment of refractory depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Naltrexone and buprenorphine combination in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Moving from the orphanin FQ receptor to an opioid receptor using four point mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Regarding "Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system".

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Orphanin FQ/nociceptin blocks methamphetamine place preference in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

P.2.b.014 Does the antidepressive response to opiate treatment describe a subtype of depression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100503

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100503

1 reference

18 August 2017

1 reference

PubMed ID

18212797